Clinical trial for efficacy and safety of EICUF on reducing body weight and body fat of overweight or obesity subjects
- Conditions
- Endocrine, nutritional and metabolic disease
- Registration Number
- KCT0003809
- Lead Sponsor
- Woogjin Foods
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 100
1) Adult male and female between 20-65 years
2) BMI=25kg/m^2 and <32kg/m^2
3) Subject who voluntarily agrees to participate and sign in informed consent form
1) Subject with severe cerebrovascular disease (infarct, hemorrage), cardiac disease (angina, myocardiac infarct, heart failure, arrhythmias that require treatment) within recent 6 months. (If that patient's clinical status is stable, they can participate in the clinical trial according to investgator)
2) Subject who was taking drugs that affect body weight within the past month (including absorption inhibitors and appetite suppressants, health functional foods / supplements related to obesity improvement, psychiatric drugs such as depression, beta blockers, diuretics, birth control pills, steroids)
3) Patients with uncontrolled hypertension (systolic BP = 160 mmHg or diastolic BP = 100 mmHg, after 10 minutes of test subjects)
4) Subjects who fasting blood glucose = 126 mg/dL or diabetic patients use of hypoglycemic agent or insulin
5) Subject who TSH = 0.1 µU/ml or = 10 µU/ml
6) Subject who more than 2times the the upper limit of normal Serum creatinine of clinical trial institution
7) Subject who more than 3times the upper limit of normal AST(GOT) or ALT(GPT) of clinical trial institution
8) Subject with severe gastrointestinal disorders that have a problem with taking test material
9) Subject who are admitted to hospital, medication or rehabilitation due to alcohol use disorder ? related disorder, heart disease, central nervous disorder, etc. through medical history
10) Subject who are judged to be unable to exercise due to musculoskeletal disorders
11) Subject who participated in the commercial obesity program within the last 3 months
12) Subject who have participated or planned to participate in other clinical trials within the past month
13) Subject who is pregnant or is lactating or has a pregnancy plan during the period of the clinical trial
14) Subject who the opinion investigator make a judgment to be unsuitable for any other reason
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percent Body Fat, Body Fat Mass by DEXA(Dual-energy X-ray absorptiometry)
- Secondary Outcome Measures
Name Time Method weight;Waist Circumference, Hip Circumferenc, Waist to Hip Ratio;Body Mass Index(BMI);Lean Mass by DEXA(Dual-energy X-ray absorptiometry);Visceral Fat Area, Subcutaneous Fat Area, Taoal Fat Area,Visceral fat / Subcutanesou Fat Ratio by CT;Total Cholesterol, HDL-Cholesterol, LDL-Cholesterol, Triglyceride;Adiponectin, hs-CRP, Leptin;treatment-emergent adverse events(TEAEs);Vital Sign(pulsus, arteriotony);clinical laboratory test(hematologic/chemistry examination, Urinalysis);electrocardiography